anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present disclosure relates to a digital medicine companion for patients undergoing oncology treatments. A patient may enter symptoms on a prescription software. A wearable device may passively collect other healthcare data such as biological data and/or physical activity data. The patient may therefore be monitored using the prescription software and/or wearables. Furthermore, the prescription software may be integrated with biofluid testing systems. For example, an at-home biofluid monitoring kit and/or a laboratory system may communicate with the prescription software and/or its backend server. The healthcare data collected through the monitoring and the biofluid testing may be fed into a machine learning model, which may output whether the patient is likely to develop side effects such as cytopenia. One or more alert notifications, e.g., to a clinician dashboard and/or to the prescription software, may be triggered when the machine learning model determines a higher likelihood of such side effects.
Cerebrovascular disease is the most common cause of death worldwide. There is a close link in structure and function between the intracranial large arteries and cerebral small vessels. Moreover, growing evidences have demonstrated that large artery atherosclerosis often coexists with small vessel disease, which may deteriorate the clinical outcomes of stroke and dementia. The mutual feedback mechanism between them is not fully understood. The present study focuses on the mechanism of mutual feedback between large artery atherosclerosis and cerebral small vessel disease by using magnetic resonance imaging. The study may provide biomarkers for the early prevention and treatment of cerebrovascular disease.
A dataset regarding a plurality of applications is obtained. A set of parameters is determined from the dataset, comprising at least a sample performance trajectory, a risk factor, and a performance outcome. A maximum likelihood of each performance outcome is determined using a likelihood function, the likelihood function being a mixture model of a trajectory model and an outcome model. The set of parameters is updated according to the maximum likelihood of each performance outcome. A performance trajectory model is built according to the updated set of parameters. The plurality of applications is then grouped into subgroups according to the performance trajectory model, each subgroup containing one or more applications, and each of the one or more applications in a given subgroup having a same or similar trajectory to each other. An alert associated with the applications in at least one of subgroups may be generated.
<P>PROBLEM TO BE SOLVED: To efficiently make a diagnosis when a doctor makes a diagnosis on the basis of medical images displayed in an operation picture.  <P>SOLUTION: The operation picture 60 displayed on the monitor of a client terminal is provided with an icon display area 61 for displaying an icon group 62 comprising a plurality of icons 62a for inputting operation instructions. The CPU of the client terminal extracts the icon recorded in an operation log from the icon group 62 and displays it as a first tool bar 70. Also, the CPU extracts the icon recorded in statistic information from the icon group 62 and displays it as a second tool bar 74. The doctor recognizes the icons operated in the past and the operation order by looking at the respective tool bars 70 and 74.  <P>COPYRIGHT: (C)2008,JPO&INPIT
This study was designed as an investigator-directed, non-commercial, observational, prospective, national, single-center study. The effect of preoperative complex ECG changes on the formation of cardiac damage will be studied. The data of the people participating in the study will be kept entirely confidential. After being informed about the study, all patients giving written informed consent will undergo preoperative evaluation. An ECG and cardiac troponin analysis will be performed to the patients who meet the eligibility. After the surgery will be completed control cardiac troponin and extensive physical examination will be performed.
<P>PROBLEM TO BE SOLVED: To solve the problem that it is impossible to convert medical data into meaningful information by being summed up and analyzed, to use the summed-up and analyzed information immediately at a medical site, and to effectively use the medical data for early restoration and rehabilitation of a patient and for avoidance of medical treatment risk.  <P>SOLUTION: A data reception terminal 11 receives medical data from a hospital system 20 and works medical data into data of a master system and a transaction system. A job server 12 stores data worked by the data reception terminal 11 and supplies data in accordance with requests of respective medical workers. An information conversion terminal 13 links medical data and data obtained in a medicine management guide job and obtains history information data for medicine management guide, which is connected to real data. An information server 14 stores history information data and supplies history information data in accordance with the request from a terminal that each medical worker uses. An application server 15 supplies application software for performing important analysis and evaluation in accordance with the request of each medical worker based on stored history information data and data.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The patient group will consist of a maximum of 350 patients (male and female subjects,18 years to 30 years of age, in command of the German language)) with congenital heart disease (Tetralogy of Fallot, Transposition of the great arteries, univentricular heart disease, ventricular septal defect) treated at the cardiologic department of the University Hospital Zurich. Eligible patients will be contacted by the study nurse during the outpatient consultation at the university hospital. No intervention.
The objective of this trial is to assess the toxicity of thymus transplantation following unrelated umbilical cord blood transplantation. Emphasis will be placed on adverse events that are not typically associated with umbilical cord blood transplantation. Also, to determine whether engraftment of a third party thymus allograft is feasible in patients who have undergone unrelated umbilical cord blood transplantation. Thymic engraftment will be determined by biopsy of the thymus allograft and immunohistochemical evidence of thymopoiesis. In addition, we would like to assess thymic function by measuring the number of naive T cells and the number of T cell receptor rearrangement excision circles (TRECS), and by assessing the diversity of the T cell receptor beta chain. These data will be compared to age, stem-cell donor source and disease matched historical controls whose stem cell transplants were not followed by a thymus transplant. This will be done in descriptive fashion. Other immune parameters will be followed including T, B, and NK cell numbers, T cell responses to mitogens, antigens, and immunoglobulin production.
The control group consisted of 50 people of the same age and sex, who had never smoked neither cigarette nor waterpipe. Breath carbon monoxide, pulmonary function tests were performed and parameters of oxidative stress were measured in blood samples.
BACKGROUND: For some COVID-19 patients, symptoms and health impairments persist for an extended period of time (long COVID). Long-term consequences of the disease can lead to permanent limitations in participatory life. In these cases, medical rehabilitation may be useful. Due to the novelty of the disease, little is known about the need for rehabilitation and therapy and the health benefits of specific rehabilitation interventions.
METHODS: A multicentre longitudinal observational study was conducted. Persons affected by long COVID (LC) between 18 and 65 years of age undergoing pulmonary rehabilitation were included. An age-matched comparison group (CG) consisted of rehabilitation patients with bronchial asthma and COPD. Written questionnaires were administered at the beginning and end of rehabilitation, as well as six and twelve months after rehabilitation. Outcomes included parameters of subjective health, occupational outcomes, contents of rehabilitation and rehabilitation aftercare.
RESULTS: The sample consisted of 305 participants, of whom 172 were classified as LC and 133 as CG. In the total sample, one third of the participants were male and the average age was 53 years. All rehabilitation participants had high health burdens, LC patients had statistically significantly higher impairments in almost all outcomes recorded. At the beginning of rehabilitation, one third of the respondents were on sick leave, more often in LC than in the CG. Twelve months after rehabilitation, both groups achieved significant health improvement, with LC showing greater improvements in most outcomes (interaction effect p<0.01). Despite success in most parameters, LC patients still showed persistent COVID symptoms at twelve months. One year after rehabilitation, 89% returned to work.
CONCLUSION: The majority of rehabilitation patients benefit greatly from pulmonary medical rehabilitation in terms of health and occupation. The content of pulmonary rehabilitation seems to be suitable for this indication group; however, there is an indication-specific use of therapy between CG and LC group. As a result, the LC group seems to need more and different therapies.
Gastric cancer (GC) is one of the most common cancer worldwide. Neural invasion (NI) is considered as the symbiotic interaction between nerves and cancers, which strongly affects the prognosis of GC patients. Small extracellular vesicles (sEVs) play a key role in intercellular communication. However, whether sEVs mediate GC-NI remains unexplored. In this study, sEVs release inhibitor reduces the NI potential of GC cells. Muscarinic receptor M3 on GC-derived sEVs regulates their absorption by neuronal cells. The enrichment of sEV-circVAPA in NI-positive patients' serum is validated by serum high throughput sEV-circRNA sequencing and clinical samples. sEV-circVAPA promotes GC-NI in vitro and in vivo. Mechanistically, sEV-circVAPA decreases SLIT2 transcription by miR-548p/TGIF2 and inhibits SLIT2 translation via binding to eIF4G1, thereby downregulates SLIT2 expression in neuronal cells and finally induces GC-NI. Together, this work identifies the preferential absorption mechanism of GC-derived sEVs by neuronal cells and demonstrates a previously undefined role of GC-derived sEV-circRNA in GC-NI, which provides new insight into sEV-circRNA based diagnostic and therapeutic strategies for NI-positive GC patients.
A preparation method of a tumor microparticle encapsulating a metabolic inhibitor includes following steps. A tumor cell is cultivated, and a statin drug is added to a culture medium after the tumor cell grows stably. Then, the tumor cell is irradiated with an ultraviolet, and then the tumor cell is incubated in a cell incubator for 22˜26 hours. After the incubation, cell supernatant is collected and the tumor microparticle encapsulating the metabolic inhibitor is obtained through a gradient centrifugation. The preparation method uses tumor cell-derived microparticles as drug delivery platforms, with a simple preparation process that preserves functions such as biosafety, biocompatibility, targeting, and intercellular communication. The preparation method discovers new uses of a statin drug, which can inhibit tumor growths with the statin drug, regulate tumors metabolism and improve a tumor microenvironment, and have a potential to enhance a chemotherapy efficacy and delay a chemotherapy resistance.
Likuni Phala. Counseling + Vitamin A as for ST-DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
Participants in the control group will receive messages about health topics unrelated to tobacco use (e.g., sun safety). Messages will be delivered online through 4 brief study communications.
To develop an echocardiography image quality management system based on deep learning to achieve objective and accurate automatic echocardiography image quality control. A total of 2000 patients performing transthoracic echocardiography were prospectively enrolled in the Department of Ultrasound Medicine of the Affiliated Drum Tower Hospital with Medical School of Nanjing University. The inclusion criteria: Patients with standardized TTE view segmentation; The exclusion criteria: Patients with incomplete standard segmentations. The data of 8 TTE view segmentations were collected, including the views of the parasternal long axis of the left ventricle (PLAX_LV), parasternal short axis of the large vessel level (PSAX_GV), parasternal short axis of the mitral valve level (PSAX_MV), parasternal short axis of the papillary muscle level (PSAX_PM), parasternal short axis of the apical level (PSAX_AP), apical four cavity (A4C), apical three cavity (A3C), apical two cavity (A2C). The data of 1500 patients were used as the training set, and the rest were used as the validation set. These video data were classified into corresponding view segmentations and analyzed by the Video Swin Transformed Model. Then, the scoring module of different view segmentations combined key frame extraction, image segmentation, video target recognition and video classification model were established. At the same time, the scores achieved by the automatic echocardiography image assessment system were compared with the artificial score. By constantly correcting and learning and eventually building an primary automated grading system. At last, the echocardiography image quality management system was performed on the rest 500 patients and improved.
From July 1, 2009 - December 31, 2010, all odd-birth-date residential births in Durham County, North Carolina were randomly assigned to a control group condition. These families were assigned to receive services as usual and served as the randomized comparison group for evaluating Durham Connects program impact.
Group 4. N=5. 1 drop of 100U/mL insulin administered twice daily for 5 days.
By January 2015, oncology care providers will be expected to craft Survivorship Care Plans (SCPs) for all individuals ending active treatment for cancer; however, there is a lack of systematic study of the impact survivorship planning has on patients, providers, or healthcare systems. The Polaris Oncology Survivorship Transition (POST) program is a web-based system that incorporates recommendations from the Institute of Medicine (IOM) and American College of Surgeons (ACS) to assist with cancer survivorship planning. It is a patient-centered approach that integrates input from both the treating oncology team and the patient. Phase 1 built and iteratively modified (N=25) the POST system and Phase 2 will test whether the SCPs impact patient and provider outcomes using a single blind, randomized controlled trial (RCT). Breast cancer patients (n=230) transitioning out of active treatment will be recruited and randomly assigned to receive Treatment as Usual (n=115) or the POST (n=115). All participants will be assessed at 1, 3, and 6 months by a research assistant blind to baseline status and group assignment. Primary outcomes will include quality of life, mechanisms of action such as confidence in entering survivorship, and other outcomes such as (1) depression and anxiety, (2) adherence to medical and behavioral health recommendations, (3) health care utilization, and (4) patient and provider satisfaction with the POST system.The POST will innovate the clinical setting through being the first system to produce computer generated tailored survivorship plans fully reflecting IOM recommendations and the new ACS 2015 requirements; incorporating information from both the oncology provider and the patient; featuring readily available "plug in" for two-way electronic health record integration; providing dynamic, electronic referrals for specialized support services; and facilitating care coordination between the oncologist and PCP. This study's impact will be significant. If hypotheses are confirmed, clear scientific evidence will exist for supporting survivorship care planning into oncology clinical practice. If hypotheses are disconfirmed, important lessons will guide future directions for care planning, including whether failure to affect outcomes was due to failure to impact several hypothesized mechanisms of action.
This invention belongs to molecule biology and biomedicine technique field. It relates to 9 target points of RNA disturbing to HBV and applications of preparing hepatitis B medicine according to these target sequence. Plasmid is expressed through shRNA and siRNA transfection cell and animal cell is chemical synthesized. Then 16 RNA target point on HBV tissue is sieved, 9 of them can obvious restrain HBV protein expression at cell level. Expression and virus duplication of HBV protein inside cell can be stably restrained by 11 target point, and expression of HBV transgene little mouse in vivo virus protein can be restrained. Medicine curing hepatitis B can be made according to these target sequence.
BACKGROUND: In recent years, Autoimmune diseases (ADs) and hearing loss are both significant public health burdens worldwide. An increasing number of studies are focusing on the potential link between these two diseases and exploring how hearing loss can be prevented and treated in the context of autoimmune diseases. In response to this focus, it is very necessary to conduct bibliometric analysis and molecular mechanism exploration to provide guidance for the exploration of basic mechanisms and clinical management.
METHOD: Studies focusing on hearing loss and autoimmune disease were extracted from the Web of Science Core Collection database from 2000 to 2024. Bibliometric and visual analysis of the collected publications was conducted using VOSviewer and CiteSpace. The investigation of molecular pathways associated with diseases was carried out in the GeneCards and STRING databases.
RESULTS: A total of 696 papers met the inclusion and exclusion criteria and were chosen for further research. The number of papers on hearing loss and autoimmune diseases is increasing every year. These papers were mainly from 65 countries, led by the United States, China and Italy. These investigations included 3505 authors in total, with Greco A contributing the most publications. Harvard Medical School and Sapienza University Rome were the two institutions with the highest number of publications. Otology & Neurotology was the journal with the highest number of publications. The most common keywords include " sensorineural hearing loss", "endolymphatic hydrops", "management" and "autoimmune", which represent current and prospective future research trends and target topics in the field. Among them, the highest proportion of hearing loss in autoimmune ear diseases is sensorineural hearing loss, and the highest proportion of primary autoimmune ear diseases is Autoimmune inner ear disease. In addition, A total of 295 potential targets common to both diseases were also identified. Their pathogenesis involves cancer pathways, infectious disease pathways, cell senescence, epithelial and myocyte proliferation, hypoxia response, and inflammatory response.
CONCLUSION: This bibliometric analysis reveals global research trends on hearing loss in the context of autoimmune diseases. Based on this, combined with preliminary bioinformatics analysis, a potential yet close link between the autoimmune diseases and hearing loss has been demonstrated. The current study highlights the need to fully consider the common genetic and pathophysiological mechanisms of these two types of diseases to promote interdisciplinary research and the development of personalized treatments for this clinical focus, with particular attention to the elderly population with comorbidity diseases. A deeper understanding of disease mechanisms has also led to advances in the clinical management of autoimmune ear diseases, including diagnosis and treatment.
Participants were to receive AVP-786-28 (deudextromethorphan hydrobromide \[d6-DM\] 28 milligrams \[mg\]/quinidine sulfate \[Q\] 4.9 mg) once daily (OD) for the first 7 days, followed by AVP-786-28 twice daily (BID) for the next 7 days. Beginning on Day 15, participants were to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) BID for 10 weeks.
The initial goal of hearing aids is to amplify speech and facilitate speech understanding especially in noise. Besides speech difficulty, people with hearing loss also report a reduced enjoyment of music. The hearing aid settings used for amplifying speech often have adverse effects on music.

For this study, the sponsor will carry out testing with participants with hearing loss to compare dedicated music programs. The current study will compare the standard music program available in the software to one that is fine-tuned for each subject. The hearing aids that will be used for the study are certified by the European Conformity and have been on the market for almost one year. The goal is to determine whether musicians will perceive a difference and prefer a fine-tuned music program over the default music program in real-life situations.
PURPOSE/BACKGROUND: A weight-based dosing approach of 20-30 mg/kg per day of valproic acid (VPA) has been shown to achieve rapid attainment of mood symptom control. Due to interindividual pharmacokinetic variability, therapeutic drug monitoring may be a useful tool to avoid VPA toxicity. Limited research exists on the impact of patient body weight on VPA pharmacokinetic profiles. This analysis aims to explore the correlation between steady-state serum levels of VPA and weight-based dosing strategies, including total body weight (TBW), ideal body weight (IBW), and adjusted body weight (AdjBW), between obese and nonobese patients.
METHODS/PROCEDURES: This single-center, retrospective, observational cohort analysis evaluated weight-based dosing of VPA in obese and nonobese patients admitted to inpatient psychiatry at a large academic medical center between July 1, 2017, and July 1, 2022.
FINDINGS/RESULTS: This analysis included 93 obese and 93 nonobese patients. No significant difference in median VPA serum concentrations was observed between groups ( P = 0.82). However, the obese group received a lower median weight-based dose (15.6 mg/kg) compared with the nonobese group (19.5 mg/kg, P < 0.001). A stronger correlation was found between VPA dose and therapeutic serum levels in the obese group compared with the nonobese group regardless of weight-based dosing strategy. Dosing with AdjBW in obese patients most closely approximated dosing with TBW in nonobese patients.
IMPLICATIONS/CONCLUSIONS: In obese patients, our analysis suggests dosing VPA using AdjBW may be considered as the preferred dosing strategy over IBW or TBW to minimize toxicity risk. Further research is needed with larger sample sizes and diverse patient populations to confirm these findings.
Health education sessions. 50 minutes per session, 2 times per week, 8 weeks.
The invention belongs to a traditional Chinese medicine, and particularly relates to a traditional Chinese medicine for treating solar dermatitis. The invention is characterized in that the traditional Chinese medicine is composed of the following components in parts by weight: 8-12g of radix rehmanniae, 8-12g of wild chrysanthemum flower, 13-17g of red paeonia, 13-17g of taraxacum, 13-17g of herba houttuyniae and 4-8g of licorice. The traditional Chinese medicine is decocted with clear water and taken 1 dose a day. The decoction is taken by three times and 1 dose a day. The decoction dregs are decocted with water, cooled, and used for washing or being wetly applied to the affected part. The patient can recover within 5-7 days. The invention is on the basis of the traditional Chinese medicine authentication theory, has the advantages of simple formula, accessible materials, low cost, high curative effect and no toxic or side effect, and effectively treats solar dermatitis.